Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, has scheduled its Q1 2025 earnings conference call and webcast for May 13, 2025, at 4:30 p.m. ET. The company will discuss financial results for the quarter ending March 31, 2025, and provide corporate updates.
Participants can join via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) using conference ID: VERRICA. The webcast will be accessible through Verrica's investor relations website and will remain archived for 90 days after the event.
Verrica Pharmaceuticals (NASDAQ: VRCA), azienda specializzata in terapie dermatologiche, ha programmato la conferenza telefonica e la diretta web per la presentazione dei risultati del primo trimestre 2025 per il 13 maggio 2025 alle 16:30 ET. Durante l'incontro verranno illustrati i dati finanziari relativi al trimestre chiuso il 31 marzo 2025 e forniti aggiornamenti aziendali.
I partecipanti possono collegarsi telefonicamente chiamando il numero 1-800-343-4136 (nazionale) o 1-203-518-9843 (internazionale) con ID conferenza: VERRICA. La diretta web sarà disponibile sul sito delle relazioni con gli investitori di Verrica e resterà archiviata per 90 giorni dopo l'evento.
Verrica Pharmaceuticals (NASDAQ: VRCA), una empresa de terapias dermatológicas, ha programado su llamada de conferencia y webcast de resultados del primer trimestre de 2025 para el 13 de mayo de 2025 a las 4:30 p.m. ET. La compañía discutirá los resultados financieros del trimestre finalizado el 31 de marzo de 2025 y ofrecerá actualizaciones corporativas.
Los participantes pueden unirse por teléfono marcando 1-800-343-4136 (nacional) o 1-203-518-9843 (internacional) usando el ID de conferencia: VERRICA. El webcast estará disponible en el sitio web de relaciones con inversores de Verrica y permanecerá archivado durante 90 días después del evento.
Verrica Pharmaceuticals(NASDAQ: VRCA)는 피부과 치료제 회사로서 2025년 1분기 실적 컨퍼런스 콜과 웹캐스트를 2025년 5월 13일 오후 4시 30분 ET에 예정하고 있습니다. 회사는 2025년 3월 31일 종료된 분기의 재무 결과를 발표하고 기업 최신 정보를 제공할 예정입니다.
참석자들은 국내 전화번호 1-800-343-4136 또는 국제 전화번호 1-203-518-9843으로 컨퍼런스 ID: VERRICA를 사용해 참여할 수 있습니다. 웹캐스트는 Verrica 투자자 관계 웹사이트를 통해 접속 가능하며, 행사 후 90일간 아카이브로 남아 있습니다.
Verrica Pharmaceuticals (NASDAQ : VRCA), une société spécialisée dans les thérapeutiques dermatologiques, a programmé sa conférence téléphonique et son webcast pour les résultats du premier trimestre 2025 le 13 mai 2025 à 16h30 ET. L'entreprise présentera les résultats financiers pour le trimestre clos le 31 mars 2025 et fournira des mises à jour sur la société.
Les participants peuvent se joindre par téléphone en composant le 1-800-343-4136 (domestique) ou le 1-203-518-9843 (international) en utilisant l'ID de conférence : VERRICA. Le webcast sera accessible via le site des relations investisseurs de Verrica et restera archivé pendant 90 jours après l'événement.
Verrica Pharmaceuticals (NASDAQ: VRCA), ein Unternehmen für dermatologische Therapien, hat seine Telefonkonferenz und Webcast zur Bekanntgabe der Ergebnisse für das erste Quartal 2025 für den 13. Mai 2025 um 16:30 Uhr ET angesetzt. Das Unternehmen wird die Finanzergebnisse für das Quartal zum 31. März 2025 vorstellen und Unternehmensupdates geben.
Teilnehmer können telefonisch unter 1-800-343-4136 (inländisch) oder 1-203-518-9843 (international) mit der Konferenz-ID: VERRICA teilnehmen. Der Webcast ist über die Investor-Relations-Website von Verrica zugänglich und wird 90 Tage nach der Veranstaltung archiviert.
- None.
- None.
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) reporting Q1 2025 earnings?
How can I listen to Verrica Pharmaceuticals' Q1 2025 earnings call?
How long will Verrica Pharmaceuticals' Q1 2025 earnings webcast be available?
What will be discussed in Verrica Pharmaceuticals' upcoming earnings call?
